At the 36° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA; Il ruolo della RICERCA farmacologica per la CRESCITA e la SALUTE in Italia, Torino, 23-26 ottobre 2013 data were presented on the combination of Palmitoylethanolamide and luteolin in an animal model of anxiety/depression. However, the data were presented in the absence of a proper control, PEA alone without luteolin.
The antidepressant effect of PEA+luteolin was investigated in a mouse model of anxiety/depressive-like behavior.
The effect of PEA+luteolin compound treatment (1mg/kg, i.p.), on depression-like behaviour was assessed using different paradigms such as open field, novelty suppressed feeding, forced swim test and elevated plus maze.
PEA+luteolin exerts a significant antidepressant effect. The same effects were in the past documented for PEA alone:
Yu HL1, Deng XQ, Li YJ, Li YC, Quan ZS, Sun XY. N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. Pharmacol Rep. 2011;63(3):834-9.
In the absence of a proper control these data are not very scientific. The addition of luteolin seems useless, as PEA can be dosed even high up without side effects. Furthermore, luteolin is reported to have activity as side effects, a side effect not welcome in anxiety and depression.
Source: R. Crupi, I. Paterniti, A. Ahmad, M. Campolo, E. Esposito, S. Cuzzocrea: Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. Presented at 36° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA; Il ruolo della RICERCA farmacologica per la CRESCITA e la SALUTE in Italia, Torino, 23-26 ottobre 2013.